Abeona Therapeutics.jpg
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
06 juin 2018 08h45 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 06, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
31 mai 2018 08h45 HE | Abeona Therapeutics Inc.
-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases -- Ribbon-cutting ceremony of gene and cell...
Abeona Therapeutics.jpg
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
17 mai 2018 09h20 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
14 mai 2018 08h15 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 14, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
11 mai 2018 08h15 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
02 avr. 2018 08h15 HE | Abeona Therapeutics Inc.
Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
16 mars 2018 17h10 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
15 mars 2018 08h45 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 15, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Upcoming Conference Participation
21 févr. 2018 08h45 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
06 oct. 2017 08h25 HE | Abeona Therapeutics Inc
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...